Navigation Links
Peptimmune Presentations at Upcoming Events
Date:10/28/2008

CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P. Mathers will provide an update on the Company's current phase Ib clinical trial for PI-2301 in multiple sclerosis patients at the three upcoming events:

1. BIO Investor Forum 2008. The presentation will take place on Wednesday,

October 29th, at 3:15 p.m. in the Pacific Room at the Palace Hotel in

San Francisco.

2. Oppenheimer 19th Annual Healthcare Conference. The presentation will

take place on Tuesday, November 4th, at 10:40 a.m. in the Louis XVI

Room at the Waldorf-Astoria Hotel in New York City.

3. Rodman & Renshaw 10th Annual Healthcare Conference. The presentation

will take place on Wednesday, November 12th, at 2:25 p.m. in the Adams

Room at the New York Palace Hotel in New York City.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peptimmune Announces First Close of Series D Private Financing
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
4. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... The global genotyping market is expected ... forecast period of 2015 to 2020 to reach $17.0billion ... drug discovery and development process and to provide personalized ... to this,heavy investments by key manufacturers to offer advanced ... market growth. Browse 113 market data tables & 37 ...
(Date:5/20/2015)...  Marc Tessier-Lavigne, president of The Rockefeller University, ... from The Marie-Josée and Henry R. Kravis Foundation ... will be the centerpiece of the University,s major ... Kravis Research Building, two stories high, will be ... city blocks following the shoreline of the East ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4
... Inc. (NYSE:,LDR), a recognized leader in personal ... of Michael Leatherman and David,Meador to its ... an independent consultant focused in,information technology strategies ... Financial Officer, Chief Information Officer and,Executive Vice ...
... with Retasure , ... Wake Forest, NC (PRWEB) August ... in risk assessment for diabetics, recently announced that the Carilion Clinic ... imaging risk assessment to diabetic patients., , ,Carilion Medical Group is ...
... DIEGO, Aug. 28 Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ... nervous system disorders, including obesity, today announced,that the Company ... BioCentury Newsmakers in the Biotech Industry Thursday, ... Broadway Hotel, New York, UBS Global Life Sciences ...
Cached Biology Technology:Landauer, Inc. Appoints Two New Members to Board of Directors 2Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure 2
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... DENVER Babies born to obese mothers are ... brain development, according to a study to be presented ... annual meeting in Denver. In nonpregnant adults, obesity-related ... increasing the risk of iron deficiency anemia. When a ...
... (NYSCF) applauds the US Court of Appeals for the District ... ruling against the use of public funds for embryonic stem ... stem cell research and the nation,s scientific community. Most ... world suffering from incurable diseases," says Susan L. Solomon, CEO ...
... Md. - Digging in the ground to plant trees may ... civic affairs, concludes a new University of Maryland study, based ... more a person is involved in environmental stewardship, the more ... says the report, " Digging Together ", which the researchers ...
Cached Biology News:Digging in dirt, Arbor Day planting, may help build citizenship: UMD study 2
... time to just 15 minutes! The name ... can be drawn between this exciting new laboratory ... foods. Instant meals consumed by astronauts, explorers ... are reconstituted by adding water. The Instant ...
APO(a) EIA Sample Size: 25 l...
...
Request Info...
Biology Products: